Prolonged Single-Agent Versus Combination Chemotherapy in Indolent Follicular Lymphomas: A Study of the Cancer and Leukemia Group B

Peterson, Bruce A.; Petroni, Gina R.; Frizzerà, Glauco; Barcos, Maurice; Bloomfield, Clara D.; Nissen, Nis I.; Hurd, David D.; Henderson, Edward S.; Sartiano, George P.; Johnson, Jeffrey L.; Holland, James F.; Gottlieb, Arlan J.

doi:10.1200/jco.2003.05.128

Cited by 99 publications

(45 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1,3,[19][20][21][22] They demonstrate that remissions can be achieved in a large proportion of patients but that an improvement in remission rate does not translate into a prolongation of TTF, RD, or even OS. 23,24 In contrast, recent data clearly demonstrate that the addition of rituximab to chemotherapy (R-chemo) has a significant impact on response rates and long-term outcomes.…”

Section: Discussionmentioning

confidence: 99%

Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas

Nickenig

Dreyling

Hoster

et al. 2006

Cancer

View full text Add to dashboard Cite

BACKGROUND.In patients with advanced‐stage follicular lymphoma (FL) and mantle cell lymphoma (MCL), conventional chemotherapy remains a noncurative approach, and no major improvement in overall survival has been achieved in recent decades.METHODS.The German Low‐Grade Lymphoma Study Group performed a randomized trial comparing combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) chemotherapy with combined mitoxantrone, chlorambucil, and prednisone (MCP) chemotherapy as first‐line therapy for patients with advanced‐stage FL or MCL.RESULTS.Three hundred sixty‐three patients with advanced‐stage FL (n = 277 patients) or MCL (n = 86 patients) entered the trial and were evaluable fully. CHOP resulted in a significantly higher overall response rate in patients with FL (91% vs. 82%; P = .026) and a similar tendency in patients with MCL (87% vs. 73%; P = .080). However, no significant differences were observed in the time to treatment failure or in overall survival. CHOP produced significantly more nonhematologic toxicities, whereas MCP was associated with more severe hematologic side effects. The proportion of patients who successfully underwent peripheral blood stem cell collection was significantly lower after MCP (44% vs. 93% after CHOP; P = .0003).CONCLUSIONS.Taking into account that, currently, chemotherapy regularly is combined with rituximab as first‐line therapy for FL and MCL, the data from this study may have an impact on the type of chemotherapy to be applied in such combinations. Particularly in younger, high‐risk patients who are candidates for autologous stem cell transplantation, CHOP should be preferred over MCP. Cancer 2006. © 2006 American Cancer Society.

show abstract

Section: Discussionmentioning

confidence: 99%

Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas

Nickenig

Dreyling

Hoster

et al. 2006

Cancer

View full text Add to dashboard Cite

show abstract

“…Additionally, most studies show that about 20% of patients never relapse or die from the disease, for example, one study in the pre-rituximab era showed no recurrence of disease in a cohort of patients who were followed for 20 years. 5 These studies have illustrated that the biological behavior of follicular lymphoma is markedly heterogeneous.…”

mentioning

confidence: 99%

Follicular lymphoma in young adults: a clinicopathological and molecular study of 200 patients

et al. 2013

View full text Add to dashboard Cite

Follicular lymphoma is clinically heterogenous, and therefore necessitates the identification of prognostic markers to stratify risk groups and optimize clinical management. It is relatively rare in patients younger than 40 years, and the clinicopathologic characteristics and biological behavior in this age group are poorly understood. In the current study, samples from a cohort of 200 patients between 19 and 40 years were evaluated retrospectively with respect to clinical, histologic, and genetic features. These were then correlated with clinical outcome. The median age at presentation was 35 years with a slight female prepoderance (56%). Most of the cases are presented with nodal disease (90%). Concomitant follicular lymphoma and diffuse large B-cell lymphoma were observed in 7 (4%) patients. Immunohistologic studies showed the expression of CD10 (91%), BCL6 (97%), BCL2 (95%), MUM1/IRF4 (12%), MDM2 (17%), and CD23 (25%). BCL2 rearrangement was present in 74%, and BCL6 in 20%. The estimated overall survival of patients was 13 years (mean). The presence of anemia, elevated lactose dehydrogenase, bone marrow involvement, and high-risk follicular lymphoma international prognostic index correlated with adverse overall survival. Our findings revealed that follicular lymphoma in young adults demonstrate similarities with that of older adults, including the frequency of presentation at various anatomic sites, grade, and adverse prognostic factors.

show abstract

“…[1][2][3][4][5][6][7][8] The rational design of multidrug protocols ideally follows a number of guidelines. 7 Each drug in the prescribed protocol should exhibit substantial activity as a single agent for the cancer in question.…”

mentioning

confidence: 99%

Impact of Chemotherapeutic Dose Intensity and Hematologic Toxicity on First Remission Duration in Dogs with Lymphoma Treated with a Chemoradiotherapy Protocol

Vaughan

Johnson

Williams

2007

Veterinary Internal Medicne

Self Cite

View full text Add to dashboard Cite

Background: Dose intensity has proven to be critical in maximizing chemotherapeutic efficacy for numerous human cancers. To date, the impact of dose intensity and toxicity on first remission duration has not been thoroughly assessed in dogs with lymphoma.Hypothesis: Dogs that receive maximal dose intensity will have prolonged first remission duration. Animals: Sixty-two dogs with lymphoma that were treated according to a standardized chemoradiotherapy regimen and achieved durable complete remissions were identified from the medical records database of North Carolina State University.Methods: Dosage reductions and treatment delays resulting from chemotherapy-related neutropenia were evaluated retrospectively, and each patient's actual summation dose intensity and frequency of myelotoxicity were calculated. Impact of dose intensity and frequency of neutropenia on first remission duration were evaluated by Cox proportional hazards regression.Results: Development of grade III or IV neutropenia during chemotherapy was found to be associated with prolonged first remission duration (P , .01). Dose intensity did not have a significant impact on remission duration (P 5 .07).Conclusions and Clinical Importance: Results of this study suggest that dosage reductions and treatment delays instituted to avoid repeated neutropenic episodes do not reduce first remission duration. Prolonged remission duration in patients that developed grade III or IV neutropenic episodes indicates the need for further optimization of dosing strategies for canine lymphoma patients undergoing chemotherapy.

show abstract

Prolonged Single-Agent Versus Combination Chemotherapy in Indolent Follicular Lymphomas: A Study of the Cancer and Leukemia Group B

Cited by 99 publications

References 62 publications

Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas

Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas

Follicular lymphoma in young adults: a clinicopathological and molecular study of 200 patients

Impact of Chemotherapeutic Dose Intensity and Hematologic Toxicity on First Remission Duration in Dogs with Lymphoma Treated with a Chemoradiotherapy Protocol

Contact Info

Product

Resources

About